MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Neuroprotective Effects of Combined Administration of Coenzyme Q10 and Vitamin-E in Chronic Cerebral Hypoperfusion-Induced Neurodegeneration in Rats

    WMY. Mohamed, MA. Alazimi (Kuantan, Malaysia)

    Objective: This study assessed the neuroprortective effects of combination of CoQ10 with vitamin E in Chronic Cerebral Hypoperfusion-induced neurodegeration (CCH-ND) model of rat. Background: Alzheimer’s…
  • 2019 International Congress

    Praxis deficits in patients with Parkinson’s disease: A neuropsychological study

    E. Rounis, G. Pizzamiglio (Oxford, United Kingdom)

    Objective: 1. To identify presence and subtypes of apraxia in patients with idiopathic Parkinson’s Disease. 2. To relate praxis deficits in IPD to clinical UPDRS,…
  • 2019 International Congress

    Prodromal symptoms in clinically diagnosed dementia with Lewy bodies stratified by Lewy body pathology on autopsy

    K. Wyman-Chick, D. Weintraub, M. Rosenbloom, L. Erickson, P. Martin, T. Barclay, M. Barrett (Bloomington, MN, USA)

    Objective: Compare prodromal neuropsychiatric, sleep, and motor symptoms in patients clinically diagnosed with dementia with Lewy bodies (DLB) with and without Lewy body pathology on…
  • 2019 International Congress

    Evaluation of nigral neuronal apoptosis during postnatal development and adulthood of mice strains with differential sensitivity to MPTP

    Y. H, V. Dj, C. Sagar, R. Tr, P. Alladi (Bangalore, India)

    Objective: Compare nigral neurons in C57BL/6J, CD-1 and their F1 crossbreds with respect to developmental apoptosis in the nigra during postnatal and to assess MPTP-induced…
  • 2019 International Congress

    Mitigation Effects of a Novel Herbal Medicine Hepad, on neurophysiology.

    BJ. Park, DH. Kim, JM. Park (Daejeon, Republic of Korea)

    Objective: Therefore, further studies are needed to identify compounds that can modulate the disease process and prevent the progression of symptoms in affected patients. Our…
  • 2019 International Congress

    Longitudinal analysis of the relation between trajectories of dopaminergic agonists use and BMI in Parkinson’s disease

    F. Artaud, PC. Lee, M. Vidailhet, JC. Corvol, A. Elbaz (Saint-Aubin, France)

    Objective: To describe the longitudinal relation between dopaminergic agonists (DA) use and change of BMI in a longitudinal cohort of PD patients followed annually up…
  • 2019 International Congress

    Inflammatory Conditions in Parkinson’s Disease

    B. Krishnamachari, S. Shermon, M. Goldfinger, A. Leder, B. Harper, J. Donoghue (Old Westbury, NY, USA)

    Objective: The goal was to conduct a case-control study to assess associations between Parkinson disease (PD) and inflammatory conditions including allergies, asthma, eczema, atopic conditions,…
  • 2019 International Congress

    Patterns of Lewy body dementia diagnosis and treatment in Florida

    M. Armstrong, R. Eisinger, C. Garvan, B. Patel (Gainesville, FL, USA)

    Objective: To characterize the demographic and treatment characteristics for the Lewy body dementia (LBD) population in Florida using a statewide clinical data research network. Background:…
  • 2019 International Congress

    Development of a Predictive Model for Progressive Supranuclear Palsy Using Real World Data

    E. Viscidi, Y. Zabar, T. Dam, M. Juneja, J. Kupferman, V. Kupelian, S. Eaton, I. Litvan, G. Hoglinger (Cambridge, MA, USA)

    Objective: To examine diagnoses and symptoms in progressive supranuclear palsy (PSP) patients in the 5 years before PSP diagnosis and to develop a model to…
  • 2019 International Congress

    Structural changes in non-manifesting GBA mutation carriers and GBA mutation carriers with Parkinson’s disease

    T. Yousaf, M. Kershaw, V. Suarez Contreras, P. Vickers, G. Pagano, M. Politis (London, United Kingdom)

    Objective: We aimed to investigate whether GBA mutations are associated with structural abnormalities in a cohort of GBA mutation carriers with and without manifested PD.…
  • « Previous Page
  • 1
  • …
  • 144
  • 145
  • 146
  • 147
  • 148
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley